| Prev Close: | 114.58 |
|---|---|
| Open: | 113.30 |
| Bid: | 110.50 x 100 |
| Ask: | N/A |
| 1y Target Est: | 123.24 |
| Beta: | 0.41 |
| Next Earnings Date: | 22-Oct-13 |
| Day's Range: | 112.40 - 113.88 |
|---|---|
| 52wk Range: | 81.56 - 117.91 |
| Volume: | 2,473,334 |
| Avg Vol (3m): | 3,146,640 |
| Market Cap: | 85.17B |
| P/E (ttm): | 19.06 |
| EPS (ttm): | 5.93 |
| Div & Yield: | 1.88 (1.60%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Wed 6:10PM EDT)
- Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyersat TheStreet(Wed 8:30AM EDT)
- Merck to Fire 8,500 in Strategy Overhaul That Shifts R&Dat Bloomberg(Tue, Oct 1)
- [$$] Merck Revamp Should Lift Stockat Barrons.com(Tue, Oct 1)
- Amgen Suit by Alleged Professional Whistle-Blower Tossedat Bloomberg(Tue, Oct 1)
- AMGEN INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Oct 1)
- Amgen Successfully Completes Onyx Pharmaceuticals Tender OfferPR Newswire(Tue, Oct 1)
- 4 Healthcare Stock Stories for Monday Investment Wellnessat Wall St. Cheat Sheet(Mon, Sep 30)
- Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic MelanomaPR Newswire(Mon, Sep 30)
- Amgen's 10 Billion Dollar Moleculeat Seeking Alpha(Mon, Sep 30)
- China Biotech In Review: Amgen Partners With ShanghaiTech On China R&D Centerat Seeking Alpha(Sun, Sep 29)
- 5 Top Stocks Growing Their Dividends by 25% Per Yearat Motley Fool(Sat, Sep 28)
- Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall SurvivalPR Newswire(Sat, Sep 28)
- Top 5 Health-Care Tweets of the Weekat Motley Fool(Fri, Sep 27)
- Why Is This Large Biotech Company a Sound Investment?at Motley Fool(Thu, Sep 26)
Press Releases
- Amgen Successfully Completes Onyx Pharmaceuticals Tender OfferPR Newswire(Tue, Oct 1)
- Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic MelanomaPR Newswire(Mon, Sep 30)
- Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall SurvivalPR Newswire(Sat, Sep 28)
Reports
- AMGN: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Oct 2)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(Oct 2)
- Trading Report for (AMGN). A detailed report, including free correlated market...Stock Traders Daily(Oct 2)